CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
aflibercept 2.0 mgdrug
Likely dose
aflibercept 2.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01543568
NCT01543568Phase 4Completed
CompareCT.gov

AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study)

David M. Brown, M.D.·interventional·Posted Mar 5, 2012·Updated Jan 2, 2017

In Brief

A Phase 4 clinical trial evaluating aflibercept 2.0 mg for Age Related Macular Degeneration. Completed, enrolled 46 participants across 1 site.

Detailed Summary

50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg, who are incomplete responders to 2.0mg of ranibizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 5, 2012
Enrollment StartFeb 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.3 years ago

Interventions

aflibercept 2.0 mgdrug

Intravitreal aflibercept injection 2.0 mg